Since neratinib could overcome trastuzumab resistance [37] and lapatinib resistance [27], it will be interesting to assess whether the combination of pertuzumab and neratinib will also be additive in vitro and in vivo for HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.